Innovations in Microbial Biodiscovery, Targeting Silent Metabolism and New Chemical Diversity
DOI:
https://doi.org/10.17140/VROJ-1-104Keywords:
Microbial biodiscovery, Antibiotics, Anticancer, Silent metabolism, LipopolysaccharideAbstract
It is quite evident that microbial (bacteria or fungi) crude extracts contain several important bioactive compounds and some have already shown their therapeutic activity. Unfortunately, most of the compounds have not properly been evaluated for the exploration of new lead molecule. Moreover, some of the mechanisms of actions of few bioactive compounds have not been identified so far. Hence, extensive research is required to find out the activity of compounds in the microbial crude extracts and to exploit their therapeutic potential to unlock silent secondary metabolites. Therefore, this review article raise the importance of activating microbial secondary metabolites noting the need for new tools to access the full microbial genome.
References
Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. 2003; 66: 1022-1037. doi: 10.1021/np030096l
Berdy J. Bioactive microbial metabolites: A personal view. J Antibiot. 2005; 58: 1-26. Web site. http://crawl.prod.proquest. com.s3.amazonaws.com/fpcache/e406c496973d03e7326281ef-3a3966fe.pdf?AWSAccessKeyId=AKIAJF7V7KNV2KKY2N UQ&Expires=1472901756&Signature=4pJT%2BHcesaq2Aou FMa%2FioR47ss0%3D. Accessed August 28, 2016
Pelaez F. The historical delivery of antibiotics from microbial natural products-Can history repeat? Biochem Pharmacol. 2006; 71: 981-990.
Baker DD, Chu M, Oza U, Rajgarhia V. The value of natu-ral products to future pharmaceutical discovery. Nat Prod Rep. 2007; 24: 1225-1244. doi: 10.1039/b602241n
Lazzarini A, Cavaletti L, Toppo G, Marinelli F. Rare gen-era of actinomycetes as potential producers of new antibiotics. Antonie van Leeuwenhoek. 2000; 78: 399-405. doi: 10.1023/ A:1010287600557
Capon RJ. Microbial biodiscovery: Back to the future. Curr Top Med Chem. 2012; 12: 1471-1478. doi: 10.2174/ 156802612802652394
Clatworthy AE, Pierson E, Hung DT. Targeting virulence: A new paradigm for antimicrobial therapy. Nat Chem Biol. 2007; 3: 541-548. doi: 10.1038/nchembio.2007.24
Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dow-zicky MJ. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn. Microbiol Infect Dis. 2005; 52: 215-227. doi: 10.1016/j.diagmicrobio.2005.06.001
Draghi DC, Tench S, Dowzicky MJ, Sahm DF. Baseline in vitro activity of tigecycline among key bacterial pathogens ex-hibiting multidrug resistance. Chemotherapy. 2008; 54: 91-100. doi: 10.1159/000118660
Wang J, Soisson SM, Young K, et al. Platensimycin is a se-lective FabF inhibitor with potent antibiotic properties. Nature. 2006; 441: 358-361. doi: 10.1038/nature04784
Jayasuriya H, Herath KB, Zhang C, et al. Isolation and struc-ture of Platencin: A FabH and FabF dual inhibitor with potent broad-spectrum antibiotic activity. Angewandte Chemie. 2007; 46: 4684-4688.
Singh SB, Jayasuriya H, Ondeyka JG, et al. Isolation, struc-ture, and absolute stereochemistry of platensimycin, a broad spectrum antibiotic discovered using an antisense differential sensitivity strategy. J Am Chem Soc. 2006; 128: 11916-11920. doi: 10.1021/ja062232p
Wang J, Kodali S, Lee SH, et al. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc. Natl Acad Sci USA. 2007; 104: 7612-7616. doi: 10.1073/ pnas.0700746104
Zhang C, Ondeyka J, Zink DL, Burgess B, Wang J, Singh SB. Isolation, structure and fatty acid synthesis inhibitory activi-ties of platensimycin B1-B3 from Streptomyces platensis. Chem Commun (Camb). 2008: 5034-5036. doi: 10.1039/b810113b
Zhang C, Ondeyka J, Guan Z, et al. Isolation, structure and biological activities of platensimycin B4 from Streptomyces pla-tensis. J Antibiot. 2009; 62: 699-702. doi: 10.1038/ja.2009.106
Jacob MR, Walker LA. Natural products and antifungal drug discovery. Methods Mol Med. 2005; 118: 83-109. doi: 10.1385/1-59259-943-5:083
Deresinski SC, Stevens DA. Caspofungin. Clinical Infec-tious Diseases. 2003; 36: 1445-1457. doi: 10.1086/375080
Westby M, van Dre. CCR5 antagonists: Host-targeted anti-virals for the treatment of HIV infection. Antiviral Chem Che-mother. 2005; 16: 339-354. doi: 10.1177/095632020501600601
Ziolkowska NE, Wlodawer A. Structural studies of algal lectins with anti-HIV activity. Acta Biochim Pol. 2006; 53: 617- 626. Web site. http://www.actabp.pl/pdf/4_2006/617.pdf. Ac-cessed August 29, 2016
Halfon P. Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloro-quine and an anti-viral agent. Patent Docs. 2011. Web site. http:// www.patentsencyclopedia.com/imgfull/20130121965_01. Ac-cessed August 29, 2016
Yu D, Morris-Natschke SL, Lee K-H. New developments in natural products-based anti-AIDS research. Med Res Rev. 2007; 27: 108-132.
Taubes G. The bacteria fight back. Science. 2008; 321: 356- 361. doi: 10.1126/science.321.5887.356
Chait R, Vetsigian K, Kishony R. What counters antibiotic resistance in nature? Nat Chem Biol. 2012; 8: 2-5. doi: 10.1038/ nchembio.745
D’Costa VM, King CE, Kalan L, et al. Antibiotic resis-tance is ancient. Nature. 2011; 477: 457-461. doi: 10.1038/na-ture10388
Allen HK, Donato J, Wang HH, Cloud-Hansen KA, Davies J, Handelsman J. Call of the wild: Antibiotic resistance genes in natural environments. Nat Rev Microbiol. 2010; 8: 251-259. doi: 10.1038/nrmicro2312
Wright GD. Antibiotic resistance in the environment: A link to the clinic? Curr Opin Microbiol. 2010; 13: 589-594. doi: 10.1016/j.mib.2010.08.005
Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2: 48-58. doi: 10.1038/nrc706
Qin T, Skraba-Joiner SL, Khalil ZG, Johnson RP, Capon RJ, Porco JA, Jr. Atropselective syntheses of (-) and (+) rugulotrosin A utilizing point-to-axial chirality transfer. Nat Chem. 2015; 7: 234-240. doi: 10.1038/nchem.2173
Shang Z, Khalil Z, Li L, et al. Roseopurpurins: Chemical diversity enhanced by convergent biosynthesis and forward and reverse michael additions. Org Lett. 2016; 18: 4340-4343. doi: 10.1021/acs.orglett.6b02099
Shang Z, Salim AA, Khalil Z, Bernhardt PV, Capon RJ. Fun-gal biotransformation of tetracycline antibiotics. J Org Chem. 2016; 81: 6186-6194. doi: 10.1021/acs.joc.6b01272
Khalil ZG, Raju R, Piggott AM, et al. Antimycobacterial Anthracyclines from an Australian Marine-Derived Strepto-myces sp. J Nat Prod. 2015; 78: 949-952. doi: 10.1021/acs. jnatprod.5b00095
Bok JW, Chiang Y-M, Szewczyk E, et al. Chromatin-level regulation of biosynthetic gene clusters. Nat Chem Biol. 2009; 5: 462-464. doi: 10.1038/nchembio.177
Scherlach K, Hertweck C. Triggering cryptic natural prod-uct biosynthesis in microorganisms. Org Biomol Chem. 2009; 7: 1753-1760. doi: 10.1039/b821578b
Omura S, Ikeda H, Ishikawa J, et al. Genome sequence of an industrial microorganism Streptomyces avermitilis: Deducing the ability of producing secondary metabolites. Proc Natl Acad Sci USA. 2001; 98: 12215-12220. doi: 10.1073/pnas.211433198
Bentley SD, Chater KF, Cerdeno-Tarraga AM, et al. Com-plete genome sequence of the model actinomycete Strepto-myces coelicolor A3(2). Nature. 2002; 417: 141-147. doi: 10.1038/417141a
McAlpine JB, Bachmann BO, Piraee M, et al. Microbial genomics as a guide to drug discovery and structural elucida-tion: ECO-02301, a novel antifungal agent, as an example. J Nat Prod. 2005; 68: 493-496. doi: 10.1021/np0401664
Udwary DW, Zeigler L, Asolkar RN, et al. Genome sequenc-ing reveals complex secondary metabolome in the marine acti-nomycete Salinispora tropica. Proc Natl Acad Sci USA. 2007; 104: 10376-10381. doi: 10.1073/pnas.0700962104
Elander RP. Industrial production of β-lactam antibiotics. Appl Microbiol Biotechnol. 2003; 61: 385-392. doi: 10.1007/ s00253-003-1274-y
Paranagama PA,Wijeratne EMK, Gunatilaka AAL. Uncov-ering biosynthetic potential of plant-associated fungi: Effect of culture conditions on metabolite production by paraphaeosphae-ria quadriseptata and chaetomium chiversii. J Nat Prod. 2007; 70: 1939-1945. doi: 10.1021/np070504b
Ayer SW, McInnes AG, Thibault P, et al. Jadomycin, a novel 8H-benz[b]oxazolo[3,2-f]phenanthridine antibiotic from Strep-tomyces venezuelae ISP5230. Tetrahedron Lett. 1991; 32: 6301- 6304.
Doull JL, Singh AK, Hoare M, Ayer SW. Conditions for the production of jadomycin B by Streptomyces venezuelae ISP5230: Effects of heat shock, ethanol treatment and phage infection. J Ind Microbiol. 1994; 13: 120-125. doi: 10.1007/ BF01584109
Overy DP, Smedsgaard J, Frisvad JC, Phipps RK, Thrane U. Host-derived media used as a predictor for low abundant, in planta metabolite production from necrotrophic fungi. J Appl Microbiol. 2006; 101: 1292-1300.
Cueto M, Jensen PR, Kauffman C, Fenical W, Lobkovsky E, Clardy J. Pestalone, a new antibiotic produced by a marine fungus in response to bacterial challenge. J Nat Prod. 2001; 64: 1444-1446. doi: 10.1021/np0102713
Chiang Y-M, Szewczyk E, Nayak T, et al. Molecular genetic mining of the aspergillus secondary metabolome: Discovery of the emericellamide biosynthetic pathway. Chem Biol. 2008; 15: 527-532. doi: 10.1016/j.chembiol.2008.05.010
Latifi A, Winson MK, Foglino M, et al. Multiple homologs of LuxR and LuxI control expression of virulence determinants and secondary metabolites through quorum sensing in Pseudo-monas aeruginosa PAO1. Mol Microbiol. 1995; 17: 333-343.
Bode HB. No need to be pure: Mix the cultures! Chem Biol. 2006; 13: 1245-1246.
Capon RJ. Microbial biodiscovery: Back to the future. Curr Top Med Chem. 2012; 12: 1471-1478. doi: 10.2174/15680 2612802652394
Horinouchi S, Beppu T. Autoregulatory factors and commu-nication in actinomycetes. Annu Rev Microbiol. 1992; 46: 377- 398. doi: 10.1146/annurev.mi.46.100192.002113
Kleiner EM, Pliner SA, Soifer VS, et al. Structure of the A factor, a bioregulator from Streptomyces griseus. Bioorg Khim. 1976; 2: 1142-1147.
Hashimoto M, Kondo T, Kozone I, Kawaide H, Abe H, Nat-sume M. Relationship between response to and production of the aerial mycelium-inducing substances pamamycin-607 and A-factor. Biosci Biotechnol Biochem. 2003; 67: 803-808. doi: 10.1271/bbb.67.803
Recio E, Colinas A, Rumbero A, Aparicio JF, Martin JF. PI factor, a novel type quorum-sensing inducer elicits pimaricin production in Streptomyces natalensis. J Biol Chem. 2004; 279: 41586-41593. doi: 10.1074/jbc.M402340200
Onaka H, Tabata H, Igarashi Y, Sato Y, Furumai T. Goadspo-rin, a chemical substance which promotes secondary metabo-lism and morphogenesis in streptomycetes. I. Purification and characterization. J Antibiot. 2001; 54: 1045-1053. doi: 10.7164/ antibiotics.54.1045
Asad S, Opal SM. Bench-to-bedside review: Quorum sensing and the role of cell-to-cell communication during invasive bac-terial infection. Crit Care. 2008; 12: 236. doi: 10.1186/cc7101
Antony M, Jayachandran K. Regulation of acyl homoser-ine lactone synthesis in pseudomonas putida jMQS1 under phe-nol stress. Water Air and Soil Pollution. 2016; 227: 338. doi: 10.1007/s11270-016-3018-5
Hwang I, Cook DM, Farrand SK. A new regulatory element modulates homoserine lactone-mediated autoinduction of Ti plasmid conjugal transfer. J Bacteriol. 1995; 177: 449-458. Web site. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC176609/. Accessed August 29, 2016
Jones B, Yu B, Bainton NJ, et al. The lux autoinducer regu-lates the production of exoenzyme virulence determinants in Er-winia carotovora and Pseudomonas aeruginosa. EMBO J. 1993; 12: 2477-2482. Web site. https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC413484/. Accessed August 29, 2016
Xie Y, Liu Z, Zhang G, et al. A rifampicin-resistant (rpoB) mutation in Pseudomonas protegens Pf-5 strain leads to im-proved antifungal activity and elevated production of secondary metabolites. Res Microbiol. 2016.
Cheng J, Zhang X-l, Zhao J-Y, Wen M-l, Ding Z-G, Li M-G. Recent progress of study on secondary metabolites of Strepto-myces. Zhongguo Kangshengsu Zazhi. 2015; 40: 791-800.
Sengupta S, Pramanik A, Ghosh A, Bhattacharyya M. Anti-microbial activities of actinomycetes isolated from unexplored regions of Sundarbans mangrove ecosystem. BMC Microbiol. 2015; 15: 170. doi: 10.1186/s12866-015-0495-4
Zazopoulos E, Huang K, Staffa A, et al. A genomics-guided approach for discovering and expressing cryptic metabolic path-ways. Nat Biotechnol. 2003; 21: 187-190. doi: 10.1038/nbt784
Scherlach K, Hertweck C. Discovery of aspoquinolones A-D, prenylated quinoline-2-one alkaloids from Aspergillus ni-dulans, motivated by genome mining. Org Biomol Chem. 2006; 4: 3517-3520. doi: 10.1039/B607011F
Perrin RM, Fedorova ND, Bok JW, et al. Transcriptional reg-ulation of chemical diversity in Aspergillus fumigatus by LaeA. PLoS Pathog. 2007; 3: e50. doi: 10.1371/journal.ppat.0030050
Bok JW, Hoffmeister D, Maggio-Hall LA, Murillo R, Glasner JD, Keller NP. Genomic mining for aspergillus natural products. Chem Biol. 2006; 13: 31-37.
Shwab EK, Keller NP. Regulation of secondary metabolite production in filamentous ascomycetes. Mycol Res. 2008; 112: 225-230. doi: 10.1016/j.mycres.2007.08.021
Williams RB, Henrikson JC, Hoover AR, Lee AE, Ciche-wicz RH. Epigenetic remodeling of the fungal secondary me-tabolome. Org Biomol Chem. 2008; 6: 1895-1897. doi: 10.1039/ b804701d
Raetz CRH, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem. 2002; 71: 635-700. doi: 10.1146/annurev. biochem.71.110601.135414
Rosenfeld Y, Shai Y. Lipopolysaccharide (Endotoxin)-host defense antibacterial peptides interactions: Role in bacterial re-sistance and prevention of sepsis. Biochim Biophys Acta. 2006; 1758: 1513-1522.
Khalil ZG, Kalansuriya P, Capon RJ. Lipopolysaccharide (LPS) stimulation of fungal secondary metabolism. Mycology. 2014; 5: 168-178. doi: 10.1080/21501203.2014.930530
Medema MH, Blin K, Cimermancic P, et al. antiSMASH: Rapid identification, annotation and analysis of secondary me-tabolite biosynthesis gene clusters in bacterial and fungal ge-nome sequences. Nucleic Acids Res. 2011; 39: W339-W346. doi: 10.1093/nar/gkr466
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Vaccination Research (VR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.